A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-05-28
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and potential benefit of combination
amuvatinib with standard of care chemotherapy treatment (platinum and etoposide) in small
cell lung cancer (SCLC) subjects.